In the United States, *Clostridium difficile* infection (CDI) is associated with 250 000 hospitalizations and over 14 000 deaths per year. These rates result in more than \$1 billion in excess medical cost per year, and the Centers for Disease Control and Prevention (CDC) assigned *C difficile* as an urgent hazard that requires aggressive action (<http://www.cdc.gov/drugresistance/pdf/ar-threats-2013-508.pdf>). Patients in intensive care units (ICUs) are at particularly high risk for CDI due to the presence of multiple risk factors \[[@OFV186C1]\], and CDI is the most common infectious cause of diarrhea in this setting \[[@OFV186C2]\]. Although it has been estimated that 0.9% of the general hospital population suffers from CDI \[[@OFV186C3]\], aggregate data on CDI rates among ICU patients are scarce. The purpose of this systematic review and meta-analysis is to assess the prevalence and clinical outcomes of CDI among ICU patients.

MATERIALS AND METHODS {#s2}
=====================

A systematic search of PubMed, EMBASE, and Google Scholar databases was performed for pertinent studies up to May 31, 2015. We used terms (ICU AND \[clostrid\* OR difficile OR diarrhea OR infect\* OR \[clostridium difficile\] OR pseudomembranous colitis\]) to identify all published studies reporting cases of CDI in ICU patients among the total ICU population. The terms infect\* and diarrhea were included in the search term in an effort to retrieve all articles that reported episodes of CDI along with other infections, as well as episodes of CDI along with other causes of diarrhea in ICU patients. Reference lists of the retrieved studies, systematic reviews, and meta-analyses relevant to our study were also reviewed. Our analysis included published literature and abstracts from conference proceedings published in EMBASE. The study was performed in line with the PRISMA recommendations \[[@OFV186C4]\].

Inclusion Criteria {#s2a}
------------------

All studies that reported the prevalence of CDI among patients after they were admitted in ICU were included in our meta-analysis. Studies that did not explicitly report the presence of symptoms or signs related to CDI (such as diarrhea, pain, fever, abdominal pain or tenderness) along with the subsequent laboratory confirmation were excluded because they circumvent the current CDI definition defined by the CDC and overestimate the relevant rates including *C difficile* colonization (<http://www.cdc.gov/HAI/organisms/cdiff/Cdiff_faqs_HCP.html#changed>). In an effort to include studies that had appropriately attributed the CDI cases to ICUs, we included only those that explicitly reported so or those that described symptoms and screening after 24 hours after the ICU admission. Patients who had diarrhea or CDI before they were admitted to the ICU were excluded from the analysis. In case of randomized trials, we set the criterion to include both arms if the applied intervention did not result in a significant outcome. Language restriction was imposed with the exclusion of articles published in languages other than English. Only studies that met the quality assessment criteria were included (discussed below under Quality Assessment).

Data Extraction {#s2b}
---------------

Studies that were considered for inclusion in the meta-analysis were independently evaluated by 2 reviewers (S.P. and S.K.), and discrepancies were discussed and resolved by consensus. For each study apart from prevalence, we extracted data on study population, patient demographics, study duration, study design, location, laboratory method for *C difficile* detection, time after ICU admission when they are deemed as ICU patients, lower limit of age of included patients, type and size of ICU along with type of hospital for which they serve. The primary outcome of interest was the prevalence of CDI among ICU patients and among ICU patients with diarrhea. Prevalence was calculated by dividing the number of patients diagnosed with CDI while in the ICU among the total ICU patients or among ICU patients suffering from diarrhea, respectively. Laboratory confirmation of CDI among diarrheic patients included polymerase chain reaction, enzyme-linked immunosorbent assay, cytotoxin test, other enzyme immune-absorbent technique, or stool culture. As secondary outcomes, we estimated the difference in ICU and overall (all-cause) hospital mortality risk among CDI (associated to CDI) and non-CDI patients, the difference in ICU length of stay (LoS) and overall (all-cause) hospital length among CDI and non-CDI patients, the prevalence of pseudomembranous colitis among CDI patients, and the required time for CDI manifestation upon admission to ICU. We also extracted information on patient age and Acute Physiology and Chronic Health Evaluation II (APACHE II) scores to evaluate patient characteristics and health status at ICU admission and to identify any potential difference between CDI and non-CDI patients. It is worth noting that we were unable to compare the APACHE II score between dead versus alive patients because there were no extractable data. We used studies that provided concurrently secondary outcomes in both CDI and non-CDI groups, assuring objective comparison.

Quality Assessment {#s2c}
------------------

The methodological quality of eligible studies was assessed by 2 reviewers (S.P. and S.K.) using the Newcastle-Ottawa Scale (NOS), which is a "star-based" rating system \[[@OFV186C5]\]. The 3 parameters used to evaluate the quality of individual studies were as follows: selection, comparability, and exposure/outcome assessments. The NOS assigns a maximum of 4 points for selection, 2 points for comparability, and 3 points for exposure/outcome. We considered the study population representative of the exposed cohort if data on CDI were provided for all available ICU patients and not among a specific subpopulation. The outcome was based on cases with symptoms and laboratory diagnosis of CDI. Studies that received 5 stars were considered of adequate quality for extraction of relevant information. If the study was an abstract, 4 stars were considered enough to indicate adequate quality. Any discrepancies regarding quality assessment were resolved by joint re-evaluation of the original article or abstract.

Data Synthesis and Analysis {#s2d}
---------------------------

We performed the meta-analysis using a random-effects model to estimate the pooled prevalence and the 95% confidence intervals (CIs) using DerSimonian and Laird \[[@OFV186C6]\] weights. The variance of the raw proportions was stabilized using the Freeman-Tukey arcsine methodology \[[@OFV186C7]\]. Metaprop command was used so that no studies with 0% or 100% proportions were excluded from the meta-analysis \[[@OFV186C8], [@OFV186C9]\]. To check for publication bias, we used the Egger\'s test \[[@OFV186C10]\]. Between-study variance τ^2^ estimation was used to assess statistical heterogeneity \[[@OFV186C10]\]. The effect of CDI on mortality compared with non-CDI cases was evaluated using random effects meta-analysis and reported as unadjusted risk difference (RD) estimates and 95% CIs. The effect of CDI on LoS compared with non-CDI cases was evaluated using random or fixed effects meta-analysis and reported as standardized mean of difference (SMD) estimates and 95% CIs. Median values and their interquartile ranges or range extracted from included studies were transformed to means and standard deviations according to Wan et al \[[@OFV186C11]\]. To model the time trends for CDI, an index year of each eligible study was determined, and then the model coefficients were transformed to rates and plotted against this year along with the observed prevalence rates \[[@OFV186C12]\]. The year that the study was conducted was used as the index year, and for studies whose study period extended for more than 1 calendar year the mid-year was calculated. For studies not reporting the time frame of the study conduction, we assumed that the study period was 2 years before the publication year or 1 year for the abstracts. Stata version 13 software package (Stata Corporation, College Station, TX) and Excel Microsoft Office 2010 were used to perform the statistical analysis. The statistical significance threshold was set at 0.05.

RESULTS {#s3}
=======

The initial databases search retrieved 10 083 potentially relevant citations. After screening the titles and abstracts and removing 937 duplicates, 102 studies were identified as potentially eligible for review and analysis. The articles were reviewed, and 75 articles were excluded from the final analysis. Among them, 37 studies did not provide data relevant to our study including those that did not report extractable data for our primary outcomes, 21 were review articles, 8 were case reports, 7 studies included data among patients who already had CDI before admission in ICU, 4 did not mention that the patients had diarrhea apart from positive laboratory confirmation, and 2 studies reported data in species other than human. The review of the reference lists of the full-texted articles did not add any additional studies. Finally, 22 studies were included in our meta- analysis \[[@OFV186C13]--[@OFV186C34]\], and they were coded from 23 papers \[[@OFV186C13]--[@OFV186C34]\] (2 studies included overlapped data \[[@OFV186C17], [@OFV186C35]\]). The main characteristics of the studies included in our meta-analysis are represented in Table [1](#OFV186TB1){ref-type="table"}, and the detailed selection process is illustrated in a flow chart (Figure[1](#OFV186F1){ref-type="fig"}). Table 1.Individual Studies^a^AuthorStudy PeriodMid-YearContinentStudy DesignNN Diarrhea (%)n (%)n Diarrhea (%)MethodTimeDefinitionAgeICU type (beds) HospitalAng et al \[[@OFV186C13]\]April 2004--April 20072005EuropeR Chart review1852NR62 (3.34%)NRStool cytotoxin assay\>48 hCDI: diarrhea and lab confirmation Diarrhea: ≥3 unformed stools/day for \>2 d\>18General (8) Multiple injuries (8)--Balassiano et al \[[@OFV186C14]\]January 2006--July 20092007EuropeR Chart review45821843 (9.3%)43 (19.72%)ELISA, culture, PCR targeting *tpi* gene and detecting *cdtA cdtB cdtC*NRSamples were tested at the discretion of the attending physicianNRMedical/ Surgical (30)\
TertiaryBuendgens et al \[[@OFV186C15]\]February 1999--June 20102005EuropeR Chart review3286NR110 (3.35%)NRELISA ± A/B DNA toxin detection through PCR\>48 hCDI: a new onset diarrhea with typical endoscopy image ± microbiological confirmation\>14Medical (NR)\
UniversityCustovic et al \[[@OFV186C16]\]January 2010--December 20102010EuropeP Cohort study834NR9 (1.1%)NRReference to CDCNRReference to CDCNRSurgical (NR) UniversityDodek et al \[[@OFV186C17]\]April 2006--December 20112008North AmericaR Chart review15 314NR236 (1.54%)NREIA for toxins and common antigen, cytotoxin assay (tissue culture), or PCR\>24 h (after day 2)CDI: ≥3 loose stools/day without other etiology and lab confirmation, typical pseudomembrane on endoscopy or toxic megacolon\>18Medical-Surgical\
University and communityKelly et al \[[@OFV186C19]\]March 1980--March 19811980EuropeP Cohort88330 (0.00%)0 (0.00%)Cytotoxin from fecal supernatants inoculated onto human embryonic lung fibroblast cells\>48 hCDI: diarrhea and lab confirmation Diarrhea: \>3 liquid stools a day as diarrhea\>9NRLawrence et al \[[@OFV186C20]\]July 1997--December 19991998North AmericaR Cohort1872NR40 (2.14%)NRCytotoxic assay\>24 hCDI: positive for toxin A or B in an ordered specimen by the treating ICU physician\>16Medical (19)\
Tertiary HospitalLumpkins et al \[[@OFV186C21]\]July 2004--October 20062005North AmericaP Cohort581NR19 (3.2%)NRImmunoassay for A and B toxinsNRSamples were tested per signs and symptomsNRTrauma (NR)Micek et al \[[@OFV186C22]\]January 2009--December 20102009--2010North AmericaR Cohort5852NR267 (4.6%)NRRapid membrane-filter immunoassay for both toxins A and B or real-time PCR to detect toxins or *tcdC* gene, Positive if toxin A, B, or both were detected.\>48 hCDI: diarrhea or pseudomembranous colitis and lab confirmation\>18Medical and surgical (NR)\
UniversityMusa et al \[[@OFV186C23]\]February 2003--January 20082005EuropeR Cohort5199NR27 (0.52%)NREIA\>48 hCDI: diarrhea officially defined and lab confirmation\>18Cardiothoracic\
--Noto et al \[[@OFV186C24]\]July 2012--July 20132013North AmericaR Cohort8068NR23 (0.29%)NRReference to CDCNRReference to CDC\>18Cardio (27), Medical (34), Neuro (34), Surgical (34)\
TertiaryRotimi et al \[[@OFV186C26]\]July 1999--June 20002000AsiaP Cohort212258 (3.77%)8 (32%)ELISA\>96 hCDI: diarrhea and lab confirmation ± endoscopic evidence and no other explanation for diarrhea\
Diarrhea: ≥6 loose stools/36 h\>3 moGeneral ICU (NR) Cancer ICU (NR)\
--Salva et al \[[@OFV186C27]\]January 2010--December 20112010EuropeR Chart review19361777 (0.36%)7 (3.95%)Immunochromatography or enzyme immunoassay\>48 hCDI: diarrhea and lab confirmation Diarrhea: \>3 watery stools/day or \>200 g/day stool amount\>18Medical/Surgical (34)\
TertiaryShaughnessy et al \[[@OFV186C28]\]January 2005--June 20062005North AmericaR Cohort1770NR87 (4.91%)NRELISA for toxins A and B\>48 hSample was sent on the basis of physicians\' clinical discretion\>15Medical (20)\
TertiarySilva et al \[[@OFV186C29]\]June 2005--December 20092007EuropeR Cohort10 754108015 (0.14%)15 (1.39%)ELISA for either A and/or B toxin\>72 hCDI: diarrhea or pseudomembranous colitis or toxic megacolon and lab confirmation\>18Open model (38)\
TertiaryThibault et al \[[@OFV186C30]\]For 2 months2011^b^EuropeP Cohort278422 (0.78%)2 (4.76%)NR\>24 h (up to 14 d)CDI: diarrhea and lab confirmation\
Diarrhea: ≥3 liquid stools/dayNRMixed medical/surgical (NR)\
TertiaryTripathy et al \[[@OFV186C32]\]April 2008--August 20102009EuropeR Chart review2212NR9 (0.41%)NREIA followed by GDH test and a positive toxin test\>48 hCDI: diarrhea, toxic megacolon, or ileostomy with lab confirmation, pseudomembranous colitis (endoscopy or CT), positive biopsy result, positive fecal post-mortem sample with pseudomembranous colitisNRNeuro (14--20)\
TertiaryWang et al \[[@OFV186C33]\]May 2012--January 20132012AsiaP cohort127712431 (2.43%)31 (25%)Stool DNA PCR kit for either toxin A or B detection. If positive followed by culture and toxinogenicity confirmation with multiplex PCR\>24 hSample collected if 3 or more loose stools/dayNRMedical (50)\
University hospitalZahar et al \[[@OFV186C34]\]January 1999--January 20092004EuropeP Cohort526051247 (0.9%)47 (9.18%)EIA. Positive result if either toxin A or B is detected≥72 hCDI: watery or unformed stools/day and lab confirmation of a stool sample positive\>18Medical-Surgical (NR)\
--Hasham et al \[[@OFV186C18]\]August 2009--October 20092009North AmericaP Chart review307162 (0.65%)2 (12.5%)NR\>72 hCDI: diarrhea and lab confirmation Diarrhea: \>3 episodes of loose stools/dayNRNRPinto et al \[[@OFV186C25]\]20112011^c^North AmericaR Chart Review213111632 (1.5%)32 (27.59%)PCRNRNR1 mo--21 yPediatric (NR)Tirlapur et al \[[@OFV186C31]\]January 2010-- December 20102010EuropeR Cohort11 2941278119 (1%)119 (9.31%)Antigen or toxin testNRCDI: diarrhea and lab confirmationNRNR (35)\
Tertiary[^2][^3][^4][^5] Figure 1.PRISMA flow diagram of meta-analysis. Abbreviations: CDI, *Clostridium difficile* infection; ICU, intensive care unit.

Among the 80 835 ICU patients in our analysis, the pooled prevalence of CDI was 2% (95% CI, 1%--2%; τ^2^ = 0.01) (Figure [2](#OFV186F2){ref-type="fig"}), with no evidence of small study effects across studies (Egger\'s bias 1.53, *P* = .142). The prevalence of CDI across North America studies was 2% \[95% CI (1%--4%), τ^2^ = 0.02\] \[[@OFV186C17], [@OFV186C18], [@OFV186C20]--[@OFV186C22], [@OFV186C24], [@OFV186C25], [@OFV186C28]\], whereas the estimated prevalence across Europe was 1% (95% CI, 1%--2%; τ^2^ = 0.01) \[[@OFV186C13]--[@OFV186C16], [@OFV186C19], [@OFV186C23], [@OFV186C27], [@OFV186C29]--[@OFV186C32], [@OFV186C34]\] and the estimated prevalence across Asia was 3% (95% CI, 1%--2%; τ^2^ = 0.01) \[[@OFV186C26], [@OFV186C33]\]. Among 3621 diarrheic ICU patients, the pooled prevalence of CDI was 11% (95% CI, 6%--17%; τ^2^ = 0.08), with no small study effect (Egger\'s bias 1.01, *P* = .156) \[[@OFV186C14], [@OFV186C18], [@OFV186C19], [@OFV186C25]--[@OFV186C27], [@OFV186C29]--[@OFV186C31], [@OFV186C33], [@OFV186C34]\] ([Supplementary Figure 3](http://ofid.oxfordjournals.org/lookup/suppl/doi:10.1093/ofid/ofv186/-/DC1)). Time trend plot with index year of each eligible study revealed an increasing trend in CDI among diarrheic patients (*P* = .33). Figure 2.Forest plot of included studies stratified by continent. Individuals and combined prevalence estimates of *Clostridium difficile* infection among intensive care unit patients.

Based on 4 studies \[[@OFV186C26], [@OFV186C27], [@OFV186C32], [@OFV186C34]\], we found that 25% (95% CI, 5%--51%; τ^2^ = 0.17) of ICU patients with confirmed CDI had pseudomembranous colitis determined either with imaging or endoscopic findings \[[@OFV186C26], [@OFV186C27], [@OFV186C32], [@OFV186C34]\] ([Supplementary Figure 4](http://ofid.oxfordjournals.org/lookup/suppl/doi:10.1093/ofid/ofv186/-/DC1)). It is worth noting that we excluded from this calculation the study by Buendgens et al \[[@OFV186C15]\], where only patients with pseudomembranous colitis were deemed to have CDI, in an effort to avoid overestimating the result. From 6 studies that included 391 CDI patients, the estimated pooled LoS in ICU (mean-days) before the CDI manifestation was 10.74 days (95% CI, 8.04%--13.44%; τ^2^ = 0.17) without small-study effects (Egger\'s bias 2.28, *P* = .1) \[[@OFV186C17], [@OFV186C20], [@OFV186C21], [@OFV186C23], [@OFV186C33], [@OFV186C34]\] ([Supplementary Figure 5](http://ofid.oxfordjournals.org/lookup/suppl/doi:10.1093/ofid/ofv186/-/DC1)).

Regarding LoS in the ICU, based on 5 studies and 10 327 patients, CDI patients had an average ICU stay of 23.54 days (95% CI, 19.19%--27.90%), compared with 19.16 days (95% CI, 6.06%--31.46%) for the non-CDI group. The pooled mean difference in ICU LoS was statistically significant (SMD = 0.49; 95% CI, .39%--.6%; *P* = .00) \[[@OFV186C17], [@OFV186C20], [@OFV186C21], [@OFV186C28], [@OFV186C34]\] (Figure [3](#OFV186F3){ref-type="fig"}, [Supplementary Figure 6](http://ofid.oxfordjournals.org/lookup/suppl/doi:10.1093/ofid/ofv186/-/DC1)). In terms of overall hospital LoS, based on 5 studies with 10 327 patients, CDI patients were hospitalized for 49.58 days (95% CI, 40.99%--58.16%), and non-CDI patients were hospitalized for 29.90 days (95% CI, 22.82%--36.99%) \[[@OFV186C17], [@OFV186C20], [@OFV186C21], [@OFV186C28], [@OFV186C34]\]. The pooled mean difference in hospital overall was again statistically significant (SMD = 1.15; 95% CI, .4%--1.91%; *P* = .003) (Figure [3](#OFV186F3){ref-type="fig"}, [Supplementary Figure 7](http://ofid.oxfordjournals.org/lookup/suppl/doi:10.1093/ofid/ofv186/-/DC1)). Figure 3.Forest plot of included studies. Standard mean difference (SMD) in length of stay between *Clostridium difficile* infection (CDI) and non-CDI group (A) in intensive care unit (ICU) (B) in hospital. Abbreviation: CI, confidence interval.

Based on 5 studies with 14 855 patients, the pooled mortality rate among CDI patients in the ICU was 20% (95% CI, 15%--26%; τ^2^ = 0.02), and the rate among non-CDI patients was 19% (95% CI, 17%--21%; τ^2^ = 0.00). The difference in mortality was not statistically significant (*P* = .989) (pooled RD = 0.2%; 95% CI, −27.9% to 28.3%; τ^2^ = 0.12) \[[@OFV186C15], [@OFV186C17], [@OFV186C20], [@OFV186C28], [@OFV186C33], [@OFV186C34]\] ([Supplementary Figure 8](http://ofid.oxfordjournals.org/lookup/suppl/doi:10.1093/ofid/ofv186/-/DC1)). When we assessed the overall hospital mortality based on 7 studies with 12 165 patients, the pooled mortality rate among CDI patients was 32% (95% CI, 26%--39%; τ^2^ = 0.02), and among non-CDI patients the pooled mortality rate was 24% (95% CI, 14%--36%; τ^2^ = 0.13). The difference in overall hospital mortality risk was statistically significant (*P* = .030) (pooled RD = 4.7%; 95% CI, 1%--9%; τ^2^ = 0.00) \[[@OFV186C13], [@OFV186C17], [@OFV186C20], [@OFV186C21], [@OFV186C23], [@OFV186C28], [@OFV186C34]\] (Figure [4](#OFV186F4){ref-type="fig"}, [Supplementary Figure 9](http://ofid.oxfordjournals.org/lookup/suppl/doi:10.1093/ofid/ofv186/-/DC1)). Figure 4.Forest plot of included studies. Risk difference (RD) estimate in hospital mortality between *Clostridium difficile* infection (CDI) and non-CDI group. Abbreviation: CI, confidence interval.

Evaluating the patient characteristics and morbidity between CDI and non-CDI group hospitalized in ICU, there was no statistically significant difference either in terms of age (SMD = 0.06; 95% CI, −.05% to .16%; *P* = .282 based on 5 studies with 14 343 patients) \[[@OFV186C17], [@OFV186C21], [@OFV186C22], [@OFV186C28], [@OFV186C34]\] or the APACHE II score (SMD = 0.023; 95% CI, −.37% to .42%; *P* = .911 based on 3 studies with 7922 patients) \[[@OFV186C17], [@OFV186C20], [@OFV186C22]\].

DISCUSSION {#s4}
==========

Intensive care unit patients represent an important risk group for developing CDI \[[@OFV186C36]\], and our analysis demonstrated that 2% of ICU patients manifest CDI (with lower incidence in Europe and higher incidence in the United States and Asia) and 11% of ICU patients with diarrhea are diagnosed with CDI. More importantly, regarding clinical outcomes, 1 of 4 of these patients will develop pseudomembranous colitis, and CDI in this population is associated with longer ICU and hospital stay and increased overall mortality.

The prevalence of CDI among ICU patients was significantly higher compared with what has been reported for general hospital population (0.9%) \[[@OFV186C3]\]. Diarrhea is common among ICU patients with a reported prevalence of 15%--38% \[[@OFV186C37]\]. It is notable that the estimated prevalence of CDI among diarrheic ICU patients was higher than the relevant estimation for general hospital diarrheic population (9.7%) \[[@OFV186C38]\]. These findings help us quantify the risk in this patient population and they are not surprising, because ICU patients are exposed concurrently to numerous risk factors for *C difficile*, such as treatment with multiple and broad-spectrum antibiotics, corticosteroids, proton pumps inhibitors, and enteral feeding, and they suffer from comorbidities, such as renal insufficiency, diabetes, gastrointestinal surgeries, immunodeficiency, malnutrition, and low serum albumin level that have been associated with CDI \[[@OFV186C13], [@OFV186C39], [@OFV186C40]\].

Cumulative data on ICU-acquired CDI and subsequent hospital mortality are scarce, and our analysis presents the first estimation on overall hospital mortality in this specific patient population with a rate of 32%. Of note, estimating the comorbidity scale between both groups, we confirmed that the general health status is similar, and it does not account for the difference in overall hospital mortality rates. Taken in their totality, our analysis indicates that among patients admitted in the ICU, the mortality rate is significantly higher in CDI group. It is worth noting that this higher mortality extends to the overall hospital stay, and patients with CDI and ICU admission should be closely monitored throughout their hospital stay. However, it should also be noted that we were unable to evaluate the hospital mortality attributable to CDI, and we reported all-cause mortality associated to CDI. In the general hospital population, previous reports estimated the all-cause mortality associated to CDI was between 13% and 18.6% \[44, 45\], whereas the mortality due to CDI (attributable mortality) has been reported to be approximately 7%, but this percentage referred to the era before the new aggressive virulent strains \[46\].

Of note is that prediction score tools specifically for mortality among CDI patients using variables, such as white blood count, renal function tests, levels of C-reactive protein or albumin, age, APACHE II score, presence of clinically severe disease, or cancer, can significantly contribute to the accuracy of the decision making and cost effectiveness. Although those tools have been recently developed with promising diagnostic capacity, none of them has gained widespread acceptance \[44\].

Our analysis demonstrated that the mean duration of ICU hospitalization before CDI is approximately 10 days. This finding seems to be an additional reason for physicians to minimize ICU stay by discharging or at least stepping-down ICU patients. The increased LoS of ICU and hospital stay found in our study is more difficult to analyze, because the LoS is both a risk factor as well as a consequence of CDI \[[@OFV186C34]\]. Previous studies have reported that diarrhea among critically ill patients is associated with increased LoS in the ICU \[46, 47\], whereas others argue that the increase in LoS among patients with diarrhea in the ICU is due to the severity of illness in this patient population \[48\]. Because there was no difference among CDI and non-CDI patients in terms of ICU morbidity and initial severity of illness (based on the APACHE II score), it is reasonable to assume that CDI has a direct effect in the LoS. However, it should be noted that our analysis does not allow us to quantify the direct effects of CDI in the LoS, and our estimations are unadjusted for potential confounders apart from the APACHE II score. Based on the high failure rates \[49\] and the increasing severity \[50\] and recurrence \[51\] associated with CDI, the Infectious Diseases Society of America and the Society for Healthcare and Epidemiology of America have updated the guidelines for the management of this infection \[45, 52\]. We were unable to evaluate the effect of the new guidelines on the clinical outcomes in ICU, because none of the studies conducted after 2010 provided data on mortality or LoS. In addition, regarding alternative therapies, fecal microbiota transplantation has been studied as part of the management of recurrence cases \[53\]. However, no studies evaluated this treatment in the context of severe CDI in the ICU.

CONCLUSIONS {#s5}
===========

In conclusion, ICU patients are at high risk for CDI, and the prevalence of CDI among critically ill patients was almost double that reported among the general hospital population. More than 1 of 10 cases with diarrhea suffer from CDI, and, subsequently, CDI affects adversely multiple clinical outcomes, such as the hospital mortality rate and LoS. These findings highlight the need for strict implementation of preventive policies in the critical care setting. Studies are needed to identify interventions, such as infection control measures and antibiotic stewardship programs, which may reduce the incidence and severity of CDI in this patient population.
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